GD3 Vaccines for Melanoma

Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines

Friedhelm Helling, Ann Shang, Michele Calves, Shengle Zhang, Shunlin Ren, Robert K Yu, Herbert F. Oettgen, Philip O. Livingston

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Cell surface gangliosides show altered patterns of expression as a consequence of malignant transformation and have therefore been of interest as potential targets for immunotherapy, including vaccine construction. One obstacle has been that some of the gangliosides that are overexpressed in human cancers are poorly immunogenic in humans. A case in point is GD3, a prominent ganglioside of human malignant melanoma. Using an approach that has been effective in the construction of bacterial carbohydrate vaccines, we have succeeded in increasing the immunogenicity of GD3 in the mouse by conjugating the ganglioside with immunogenic carriers. Several conjugation methods were used. The optimal procedure involved ozone cleavage of the double bond of GD3 in the ceramide backbone, introducing an aldehyde group, and coupling to aminolysyl groups of proteins by reductive amination. Conjugates were constructed with a synthetic multiple antigenic peptide expressing repeats of a malarial T-cell epitope, outer membrane proteins of Neisseria meningitidis, cationized bovine serum albumin, keyhole limpet hemocyanin, and polylysine. Mice immunized with these conjugates showed a stronger antibody response to GD3 than mice immunized with unconjugated GD3. The strongest response was observed in mice immunized with the keyhole limpet hemocyanin conjugate of the GD3 aldehyde derivative and the adjuvant QS-21. These mice showed not only a long-lasting high-titer IgM response but also a consistent high-titer IgG response (predominantly IgG1), indicating recruitment of T-cell help, although the titers of IgM and IgG antibodies following booster immunizations were not as high as they are in the response to classical T-cell-dependent antigens. This method is applicable to other gangliosides, and it may be useful in the construction of immunogenic ganglioside vaccines for the immunotherapy of human cancers expressing gangliosides on their cell surface.

Original languageEnglish (US)
Pages (from-to)197-203
Number of pages7
JournalCancer Research
Volume54
Issue number1
StatePublished - Jan 1 1994

Fingerprint

Conjugate Vaccines
Gangliosides
Melanoma
Vaccines
Immunoglobulin G
Aldehydes
Immunotherapy
Immunoglobulin M
Bacterial Vaccines
T-Lymphocytes
Amination
Secondary Immunization
Polylysine
T-Lymphocyte Epitopes
Neisseria meningitidis
Ceramides
Ozone
Bovine Serum Albumin
keyhole-limpet hemocyanin
Antibody Formation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Helling, F., Shang, A., Calves, M., Zhang, S., Ren, S., Yu, R. K., ... Livingston, P. O. (1994). GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines. Cancer Research, 54(1), 197-203.

GD3 Vaccines for Melanoma : Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines. / Helling, Friedhelm; Shang, Ann; Calves, Michele; Zhang, Shengle; Ren, Shunlin; Yu, Robert K; Oettgen, Herbert F.; Livingston, Philip O.

In: Cancer Research, Vol. 54, No. 1, 01.01.1994, p. 197-203.

Research output: Contribution to journalArticle

Helling, F, Shang, A, Calves, M, Zhang, S, Ren, S, Yu, RK, Oettgen, HF & Livingston, PO 1994, 'GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines', Cancer Research, vol. 54, no. 1, pp. 197-203.
Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK et al. GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines. Cancer Research. 1994 Jan 1;54(1):197-203.
Helling, Friedhelm ; Shang, Ann ; Calves, Michele ; Zhang, Shengle ; Ren, Shunlin ; Yu, Robert K ; Oettgen, Herbert F. ; Livingston, Philip O. / GD3 Vaccines for Melanoma : Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines. In: Cancer Research. 1994 ; Vol. 54, No. 1. pp. 197-203.
@article{6d27dc651a7549a3ad6caff6210543cf,
title = "GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines",
abstract = "Cell surface gangliosides show altered patterns of expression as a consequence of malignant transformation and have therefore been of interest as potential targets for immunotherapy, including vaccine construction. One obstacle has been that some of the gangliosides that are overexpressed in human cancers are poorly immunogenic in humans. A case in point is GD3, a prominent ganglioside of human malignant melanoma. Using an approach that has been effective in the construction of bacterial carbohydrate vaccines, we have succeeded in increasing the immunogenicity of GD3 in the mouse by conjugating the ganglioside with immunogenic carriers. Several conjugation methods were used. The optimal procedure involved ozone cleavage of the double bond of GD3 in the ceramide backbone, introducing an aldehyde group, and coupling to aminolysyl groups of proteins by reductive amination. Conjugates were constructed with a synthetic multiple antigenic peptide expressing repeats of a malarial T-cell epitope, outer membrane proteins of Neisseria meningitidis, cationized bovine serum albumin, keyhole limpet hemocyanin, and polylysine. Mice immunized with these conjugates showed a stronger antibody response to GD3 than mice immunized with unconjugated GD3. The strongest response was observed in mice immunized with the keyhole limpet hemocyanin conjugate of the GD3 aldehyde derivative and the adjuvant QS-21. These mice showed not only a long-lasting high-titer IgM response but also a consistent high-titer IgG response (predominantly IgG1), indicating recruitment of T-cell help, although the titers of IgM and IgG antibodies following booster immunizations were not as high as they are in the response to classical T-cell-dependent antigens. This method is applicable to other gangliosides, and it may be useful in the construction of immunogenic ganglioside vaccines for the immunotherapy of human cancers expressing gangliosides on their cell surface.",
author = "Friedhelm Helling and Ann Shang and Michele Calves and Shengle Zhang and Shunlin Ren and Yu, {Robert K} and Oettgen, {Herbert F.} and Livingston, {Philip O.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
pages = "197--203",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - GD3 Vaccines for Melanoma

T2 - Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines

AU - Helling, Friedhelm

AU - Shang, Ann

AU - Calves, Michele

AU - Zhang, Shengle

AU - Ren, Shunlin

AU - Yu, Robert K

AU - Oettgen, Herbert F.

AU - Livingston, Philip O.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Cell surface gangliosides show altered patterns of expression as a consequence of malignant transformation and have therefore been of interest as potential targets for immunotherapy, including vaccine construction. One obstacle has been that some of the gangliosides that are overexpressed in human cancers are poorly immunogenic in humans. A case in point is GD3, a prominent ganglioside of human malignant melanoma. Using an approach that has been effective in the construction of bacterial carbohydrate vaccines, we have succeeded in increasing the immunogenicity of GD3 in the mouse by conjugating the ganglioside with immunogenic carriers. Several conjugation methods were used. The optimal procedure involved ozone cleavage of the double bond of GD3 in the ceramide backbone, introducing an aldehyde group, and coupling to aminolysyl groups of proteins by reductive amination. Conjugates were constructed with a synthetic multiple antigenic peptide expressing repeats of a malarial T-cell epitope, outer membrane proteins of Neisseria meningitidis, cationized bovine serum albumin, keyhole limpet hemocyanin, and polylysine. Mice immunized with these conjugates showed a stronger antibody response to GD3 than mice immunized with unconjugated GD3. The strongest response was observed in mice immunized with the keyhole limpet hemocyanin conjugate of the GD3 aldehyde derivative and the adjuvant QS-21. These mice showed not only a long-lasting high-titer IgM response but also a consistent high-titer IgG response (predominantly IgG1), indicating recruitment of T-cell help, although the titers of IgM and IgG antibodies following booster immunizations were not as high as they are in the response to classical T-cell-dependent antigens. This method is applicable to other gangliosides, and it may be useful in the construction of immunogenic ganglioside vaccines for the immunotherapy of human cancers expressing gangliosides on their cell surface.

AB - Cell surface gangliosides show altered patterns of expression as a consequence of malignant transformation and have therefore been of interest as potential targets for immunotherapy, including vaccine construction. One obstacle has been that some of the gangliosides that are overexpressed in human cancers are poorly immunogenic in humans. A case in point is GD3, a prominent ganglioside of human malignant melanoma. Using an approach that has been effective in the construction of bacterial carbohydrate vaccines, we have succeeded in increasing the immunogenicity of GD3 in the mouse by conjugating the ganglioside with immunogenic carriers. Several conjugation methods were used. The optimal procedure involved ozone cleavage of the double bond of GD3 in the ceramide backbone, introducing an aldehyde group, and coupling to aminolysyl groups of proteins by reductive amination. Conjugates were constructed with a synthetic multiple antigenic peptide expressing repeats of a malarial T-cell epitope, outer membrane proteins of Neisseria meningitidis, cationized bovine serum albumin, keyhole limpet hemocyanin, and polylysine. Mice immunized with these conjugates showed a stronger antibody response to GD3 than mice immunized with unconjugated GD3. The strongest response was observed in mice immunized with the keyhole limpet hemocyanin conjugate of the GD3 aldehyde derivative and the adjuvant QS-21. These mice showed not only a long-lasting high-titer IgM response but also a consistent high-titer IgG response (predominantly IgG1), indicating recruitment of T-cell help, although the titers of IgM and IgG antibodies following booster immunizations were not as high as they are in the response to classical T-cell-dependent antigens. This method is applicable to other gangliosides, and it may be useful in the construction of immunogenic ganglioside vaccines for the immunotherapy of human cancers expressing gangliosides on their cell surface.

UR - http://www.scopus.com/inward/record.url?scp=0028180466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028180466&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 197

EP - 203

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -